REGISTRATION
isn webinar: encore presentation of empa-kidney trial data
This webinar will present newly released data from EMPA-KIDNEY trial. Three experts will discuss the primary outcomes of the trial, offer clinical interpretations of the results in practice, and address the impact of the trial results on CKD guidelines.
Learning objectives:
- Understand the EMPA-KIDNEY trial results and the meta-analysis of trials focused on kidney outcomes
- Explore clinical interpretations of EMPA-KIDNEY in practice
- Discuss how the EMPA-KIDNEY trial results will impact CKD guidelines
Further reading:
- Empagliflozin in Patients with ChronicKidneyDisease.EMPA-KIDNEY Collaborative GroupN Engl J Med. 2022 Nov 4. doi: 10.1056/NEJMoa2204233. Online ahead of print.
- Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial.EMPA-KIDNEY Collaborative GroupNephrol Dial Transplant. 2022 Jun 23;37(7):1317-1329
- ISN Infographic – Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY)
Supported by an unrestricted educational grant from Boehringer Ingelheim & Lilly